Login / Signup

Shinjulactone A Blocks Vascular Inflammation and the Endothelial-Mesenchymal Transition.

Ye-Eun JangJenita ImmanuelJin-Ri LeeYu-Jin JangYun Ju KwonHyun Sook KwonJung-Woog ShinSanguk Yun
Published in: Journal of lipid and atherosclerosis (2022)
We suggest that shinjulactone A may be an effective and safe drug candidate for atherosclerosis because it targets and inhibits both endothelial inflammation and the EndMT, without impairing NFκB-dependent innate immunity in macrophages.
Keyphrases
  • oxidative stress
  • endothelial cells
  • signaling pathway
  • stem cells
  • cardiovascular disease
  • bone marrow
  • lps induced
  • emergency department
  • pi k akt
  • type diabetes
  • cell proliferation
  • adverse drug
  • drug induced